		(Original Signature of Member)
117TH CONGRESS 1ST SESSION	H.R.	

To reduce the salary of the Director of the National Institute of Allergy and Infectious Diseases, to provide for an audit of the correspondence, financial statements, and policy memoranda within the Office of the Director during the COVID-19 outbreak, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Mrs. Greene of Georgia intro	duced the follov	wing bill; which	was referred to
the Committee on			

A BILL

To reduce the salary of the Director of the National Institute of Allergy and Infectious Diseases, to provide for an audit of the correspondence, financial statements, and policy memoranda within the Office of the Director during the COVID-19 outbreak, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- This Act may be cited as the "Fire Fauci Act".
- 5 SEC. 2 FINDINGS.
- 6 Congress finds the following:

1	(1) The Director of the National Institute of
2	Allergy and Infectious Diseases (NIAID), Dr. An-
3	thony Fauci, M.D., earned \$434,312 in 2020.
4	(2) Dr. Fauci is not only the highest paid doc-
5	tor in the Federal Government, but the highest paid
6	of any of the 4,000,000 Federal employees, includ-
7	ing the President.
8	(3) Part IV of the Executive Schedule generally
9	caps government salaries at \$172,500, but Dr.
10	Fauci's salary is much higher due to an exception
11	put in place to make Federal salaries for doctors
12	and scientists more competitive with the private sec-
13	tor.
14	(4) The role of the Director of the NIAID is to
15	"provide scientific leadership, policy guidance, and
16	overall operational and administrative coordination
17	for the Institute".
18	(5) NIAID is funded by American taxpayer dol-
19	lars and, as part of the National Institutes of
20	Health, seeks to apply scientific knowledge to "en-
21	hance health, lengthen life, and reduce illness and
22	disability".
23	(6) Dr. Anthony Fauci has continually failed to
24	provide Americans with accurate information about

1	the COVID-19 pandemic and has shown distrust in
2	the American private sector and American ingenuity.
3	(7) In March 2020, Dr. Fauci told Americans
4	not to wear masks, noting: "There's no reason to be
5	walking around with a mask. When you are in the
6	middle of an outbreak, wearing a mask might make
7	people feel a little bit better and it might even block
8	a droplet, but it is not providing the perfect protec-
9	tion that people think that it is. And, often, there
10	are unintended consequences — people keep fiddling
11	with the mask and they keep touching their face.".
12	(8) Now, more than a year later, he is telling
13	Americans to continue quarantining as much as pos-
14	sible and to wear a mask, maybe even into the year
15	2022.
16	(9) According to the Centers for Disease Con-
17	trol and Prevention, the vaccines have been "highly
18	effective" at preventing infection. Research from
19	Johns Hopkins Medicine has shown that the vaccine
20	is 95 percent effective, and also works to prevent se-
21	rious illness in the 1 in 20 people who may contract
22	COVID-19 after being vaccinated. Over
23	100,000,000 vaccines have now been administered,
24	and some studies show that those who have already
25	contracted COVID-19 may only need 1 dose of the

1	vaccine to prevent reinfection rather than the 2 pre-
2	scribed. Despite these outcomes and his previous
3	comments, Dr. Fauci has reversed course and is now
4	sounding the alarm on COVID-19 variants, com-
5	menting: "The way we can counter [the UK vari-
6	ant], which is a growing threat in our country, is to
7	do two things: to get as many people vaccinated as
8	quickly and as expeditiously as possible with the vac-
9	cine that we know works against this variant and,
10	finally, to implement the public health measures that
11	we talk about all the time masking, physical
12	distancing and avoiding congregant settings, particu-
13	larly indoors.".
14	(10) Dr. Fauci also now claims that herd im-
15	munity will require 80 to 85 percent of Americans
16	to get the vaccine.
17	(11) Dr. Fauci did not believe that American
18	companies such as Pfizer, Moderna, and Johnson &
19	Johnson would be able to produce an effective vac-
20	cine. In August 2020, he stated that the vaccine
21	might only be 50 percent effective.
22	SEC. 3. SALARY LIMITATION.
23	Section 401 of the Public Health Service Act (42
24	U.S.C. 281) is amended by adding at the end the fol-
25	lowing:

1	"(i) Rate of Pay of Director of NIAID.—
2	"(1) Reduction.—For all pay periods com-
3	mencing after the date of enactment of this Act, the
4	annual rate of pay of the Director of the National
5	Institute of Allergy and Infectious Diseases shall be
6	reduced to \$0.
7	"(2) No adjustment.—Paragraph (1) applies
8	only until a new Director of the National Institute
9	of Allergy and Infectious Diseases is appointed by
10	the President and confirmed by the Senate, exclud-
11	ing Dr. Anthony Fauci, M.D.".
	SEC. 4. TRANSPARENCY AUDIT FOR THE OFFICE OF THE
12	SEC. 4. HURNSTMEENCI MODII TOR THE OTTICE OF THE
12	DIRECTOR OF THE NIAID.
13	DIRECTOR OF THE NIAID.
13 14	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provi-
13 14 15 16	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provision of law, the Comptroller General of the United States
13 14 15 16	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provision of law, the Comptroller General of the United States shall complete an audit of the digital correspondence, pol-
13 14 15 16	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provision of law, the Comptroller General of the United States shall complete an audit of the digital correspondence, policy memoranda, and financial transactions within the Of-
13 14 15 16 17	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provision of law, the Comptroller General of the United States shall complete an audit of the digital correspondence, policy memoranda, and financial transactions within the Office of the Director of the National Institute of Allergy
13 14 15 16 17 18	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provision of law, the Comptroller General of the United States shall complete an audit of the digital correspondence, policy memoranda, and financial transactions within the Office of the Director of the National Institute of Allergy and Infectious Diseases during the period of October 1,
13 14 15 16 17 18 19	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provision of law, the Comptroller General of the United States shall complete an audit of the digital correspondence, policy memoranda, and financial transactions within the Office of the Director of the National Institute of Allergy and Infectious Diseases during the period of October 1, 2019, through December 31, 2021.
13 14 15 16 17 18 19 20	DIRECTOR OF THE NIAID. (a) IN GENERAL.—Notwithstanding any other provision of law, the Comptroller General of the United States shall complete an audit of the digital correspondence, policy memoranda, and financial transactions within the Office of the Director of the National Institute of Allergy and Infectious Diseases during the period of October 1, 2019, through December 31, 2021. (b) Report to Congress.—

1	(A) shall submit to the Congress a report
2	on the results of such audit; and
3	(B) shall make such report available to the
4	Speaker of the House of Representatives, the
5	majority and minority leaders of the House of
6	Representatives and the Senate, and any other
7	Member of Congress who requests the report.
8	(2) Contents.—The audit report under sub-
9	section (a) shall include—
10	(A) a detailed description of the digital
11	correspondence (including text messages and
12	emails) of the Director of the National Institute
13	of Allergy and Infectious Diseases from October
14	1, 2019, through December 31, 2021;
15	(B) financial transactions approved by the
16	Director of the National Institute of Allergy
17	and Infectious Diseases from October 1, 2019,
18	through December 31, 2021; and
19	(C) any memoranda or policy reports writ-
20	ten within the Office of the Director of the Na-
21	tional Institute of Allergy and Infectious Dis-
2.2.	eases related to the COVID-19 virus outbreak